Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.

导出原文传递

翻译打印收藏纠错

作者： Alex,Friedlaender ^[1] ; Giulio,Metro ^[2] ; Diego,Signorelli ^[3] ; Alessio,Gili ^[4] ; Panagiota,Economopoulou ^[5] ; Fausto,Roila ^[2] ; Giuseppe,Banna ^[6] ; Alessandro,De Toma ^[3] ; Andrea,Camerini ^[7] ; Athina,Christopoulou ^[8] ; Giuseppe,Lo Russo ^[3] ; Marco,Banini ^[2] ; Domenico,Galetta ^[9] ; Beatriz,Jimenez ^[10] ; Ana,Collazo-Lorduy ^[10] ; Antonio,Calles ^[11] ; Panagiotis,Baxevanos ^[12] ; Helena,Linardou ^[13] ; Paris,Kosmidis ^[14] ; Giannis,Mountzios ^[15] ; Marina C,Garassino ^[3] ; Alfredo,Addeo ^[1]

作者单位： Department of Oncology, Geneva University Hospital, Geneva, Switzerland. ^[1] Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy. ^[2] Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori di Milano, Milano, Italy. ^[3] Public Health Section, Department of Experimental Medicine, University of Perugia, Perugia, Italy. ^[4] Oncology Department, Attikon University Hospital, Athens, Greece. ^[5] Medical Oncology, Ospedale Cannizzaro, Catania, Italy. ^[6] U.O.C. Oncologia, Ospedale Versilia, Lido di Camaiore (LU), Italy. ^[7] Medical Oncology, Agios Andreas General Hospital of Patras, Patras, Greece. ^[8] Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. ^[9] Medical Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain. ^[10] Division of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. ^[11] Second Department of Medical Oncology, Saint Savvas Anti-Cancer Hospital, Athens, Greece. ^[12] First Department of Medical Oncology, Metropolitan Hospital, Athens, Greece. ^[13] Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece. ^[14] Second Department of Medical Oncology, Henry Dunant Hospital Center, Athens, Greece. ^[15]